Related Experiment Video
Updated: Mar 15, 2026
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
[Clinical experience with omalizumab in patients with severe asthma. Real-world data]
Jorge Bernardo Vargas-Correa1, Raúl Bracamonte-Peraza, Sylvia Marcela Espinosa-Morales
1Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Hospital Regional Mérida, Coordinación de Medicina Interna, Mérida, Yucatán, México. jbvcmer@prodigy.net.mx.
Background:
Omalizumab is a monoclonal antibody that is prescribed in a stepwise addition regimen for the treatment of severe asthma.
Objective:
To report the experience of patients with severe asthma who were given omalizumab in accordance with international guides, in a context of real-world data.
Methods:
Open, analytical, cross-sectional, retrospective, observational clinical study with real-world data. GINA 2006 Asthma Control Scheme was used to evaluate patients, and a questionnaire was used to evaluate patient characteristics, effectiveness, safety, and tolerance to omalizumab.
Results:
48 patients were studied, 34 women and 14 men with an average age of 39 years. The average disease duration was 26 years. Average serum IgE was 522 IU. At the beginning of treatment, all patients had uncontrolled asthma; at the end, 69% asthma control was obtained, 19% was partially controlled and 12% unchanged. The changes were observed at seven months on average.
Conclusion:
Omalizumab is effective and safe for treating severe asthma when applied in accordance with international guidelines for the management of bronchial asthma.
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:30Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:24Asthma-III: Symptoms and Complications
Classification of Asthma
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:26Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include: